Welcome to our dedicated page for NUMINUS WELLNESS news (Ticker: NUMIF), a resource for investors and traders seeking the latest updates and insights on NUMINUS WELLNESS stock.
Numinus Wellness Inc. reports developments in mental health care, clinical research operations, and practitioner training tied to regulated botanical wellness-assisted therapies. The company’s updates describe Cedar Clinical Research, Numinus Practitioner Training, clinical trial site readiness, therapist education, protocols, reimbursement infrastructure, and care models for depression, anxiety, trauma, pain, and substance use.
Recurring news also covers quarterly financial results, auditor changes, exchange-listing status, cease-trade-order remediation efforts, and regulatory developments affecting botanical wellness compounds such as ibogaine, MDMA, and LSD.
Numinus Wellness (OTC Pink: NUMIF) reported that it has filed all interim financial reports for fiscal 2026 to May 31, 2026 and completed the August 31, 2025 audit. According to the company, these steps position it to meet British Columbia Securities Commission requirements for revocation of the current cease trade order.
Management is continuing its application to list common shares on the Canadian Securities Exchange, with any listing contingent on meeting CSE requirements and obtaining approval. For Q3 2026, Numinus reported total revenue of $1.61 million, gross profit of $0.87 million and a gross margin of 54.4%, with revenue essentially flat quarter over quarter.
Cedar Clinical Research revenue rose 29% to $1.2 million, while Practitioner Training revenue decreased to $0.4 million, though this segment generated $0.8 million profit over the nine months ended May 31, 2026 and has been profitable each quarter since August 31, 2025. The company ended the quarter with $0.5 million in cash and a $3.8 million working capital deficiency.
Numinus Wellness (OTC Pink: NUMIF) reported Q4 fiscal 2025 revenue of $2.33 million, a 29.0% increase over Q3 2025, with gross profit of $1.42 million and gross margin of 61.2%. CCR revenue declined 13.2% to $1.4 million, while Practitioner Training revenue rose 387.6% to $1.0 million.
Operating expenses and other items increased to $2.88 million, driving a quarterly loss of $0.88 million. Numinus ended the quarter with $0.5 million in cash and a $2.7 million working capital deficiency. The company remains under a cease trade order and is focused on completing outstanding audits and interim filings to seek revocation and advance its planned CSE listing.
Operationally, CCR managed 18 clinical trials and 306 patient appointments in Q4. Practitioner Training achieved $1.2 million profit for the year. Subsequent to quarter-end, a U.S. executive order committed US$50 million to psychedelic treatment programs, which Numinus views as a supportive regulatory development. The company also appointed former CFO John Fong as an independent director and Audit Committee member.
Numinus Wellness (OTC: NUMIF) responded April 20, 2026 to a Presidential Executive Order accelerating research and access for psychedelic therapies, noting new FDA prioritization and a $50 million federal commitment to state programs. The company emphasized its clinical trial capacity and therapist training as operational enablers for faster commercialization of psilocybin, MDMA, ibogaine and LSD treatments.
Numinus highlighted Cedar Clinical Research's capacity for nearly 200 dosing sessions annually and ongoing therapist training contracts supporting an active Phase 3 program, positioning its sites and education services to support scaling if regulatory momentum continues.
Numinus (OTC: NUMIF) announced the Toronto Stock Exchange Continued Listing Committee determined to delist its common shares, effective April 22, 2026. The delisting follows prior shareholder authorization to delist and aligns with the company’s strategic considerations.
The company remains subject to a cease trade order, so its securities are not presently tradable in Canada. Numinus has filed an application to list on the Canadian Securities Exchange (CSE); any CSE listing could occur only after the CTO is revoked and the company meets CSE listing requirements. Management is prioritizing completing the 2026 audit, satisfying regulatory conditions to lift the CTO, and pursuing the CSE listing to restore trading and liquidity.
Numinus Wellness (OTCQX: NUMIF) advised a change of auditor after Horizon Assurance LLP ceased work on the audit of the August 31, 2025 financial statements and did not issue any audit opinion.
PKF Antares Professional Corporation was appointed effective February 17, 2026. Numinus says Horizon verbally resigned around January 11, 2026, no written resignation was provided, and the Audit Committee and Board approved the change.
Numinus Wellness (OTCQX: NUMIF / TSX: NUMI) provided a corporate update on December 1, 2025, describing consecutive auditor changes and ongoing regulatory review.
Key points: on Oct 10, 2025 Davidson resigned and MNP engaged; on Oct 30, 2025 MNP resigned and Horizon Assurance engaged. MNP did not complete an audit or issue opinions during its engagement.
The company has a cease trade order in force and has applied to the British Columbia Securities Commission for revocation. Numinus is addressing BCSC comments on past disclosures and incorporating feedback into the financial reporting for the year ended August 31, 2025. Timing for completing filings and lifting the cease trade order is uncertain; updates will follow.
Numinus Wellness (OTCQB: NUMIF) announced an auditor change on October 10, 2025: Davidson & Company LLP resigned and MNP LLP has been engaged as the new independent auditor.
The company stated the audit for the year ended August 31, 2025 is on track to be completed by MNP by the end of November 2025. Prior reports from Davidson for fiscal years 2020–2024 were unmodified and contained no reportable events under National Instrument 51-102. The Audit Committee and Board approved the change. The company remains in the process of lifting a cease trade order and relisting on another exchange.
Numinus Wellness Inc. (OTCQB: NUMIF), a mental health care company specializing in psychedelic-assisted therapies, reported its Q3 2025 financial results. The company achieved significant growth with revenue increasing 81.6% to $1.8 million compared to Q3 2024. Cedar Clinical Research operations saw a 95.8% revenue increase to $1.6 million, while Practitioner Training revenue grew by 12.3%.
The company demonstrated improved operational efficiency with gross margin reaching 48.2% compared to -4.6% in Q3 2024, and operating expenses decreased to $1.5 million from $3.8 million. The company ended Q3 with a cash balance of $822,835 and is working to revoke an ongoing cease trade order to relist on another exchange.
Numinus is strategically repositioning itself from a direct care provider to a comprehensive infrastructure provider for psychedelic medicine delivery, leveraging its experience of serving over 50,000 individuals across 200,000 appointments.
Numinus Wellness (OTCQB:NUMIF), a mental health care company specializing in psychedelic-assisted therapies, reported its Q2 2025 financial results. The company achieved total revenue of C$1.51 million, representing an 83.8% increase from Q2 2024. Despite revenue growth, gross profit margin declined to 33.4% from 55.6% year-over-year.
The company reported a comprehensive loss of C$7.71 million, wider than the previous year's loss of C$5.96 million. Operating expenses increased by 86.31% to C$9.89 million. As of February 28, 2025, Numinus maintained cash and cash equivalents of C$705,631.
Numinus Wellness (OTCQB: NUMIF), a mental health care company specializing in psychedelic-assisted therapies, reported its Q1 2025 financial results. The company achieved significant revenue growth of 68.3%, reaching $2.01 million compared to $1.20 million in Q1 2024.
The company demonstrated improved operational efficiency with a gross profit margin increase to 49.3% from 38.6% year-over-year. Operating expenses decreased substantially by 51.1% to $2.07 million. The net loss narrowed to $1.29 million from $4.35 million in the prior year. As of November 30, 2024, Numinus maintained a cash position of $2.0 million.